Evidence map›Paper›PMID 25407815›Full record

ArticleJournal of visualized experiments : JoVE2014

Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence.

Natalia J Sumi, Eydis Lima, John Pizzonia, Sean P Orton, Vinicius Craveiro, Wonduk Joo, Jennie C Holmberg, Marta Gurrea, Yang Yang-Hartwich, Ayesha Alvero and 1 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Natalia J SumiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Eydis LimaDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
John PizzoniaNatureMost Laboratories.
Sean P OrtonBruker Preclinical Imaging.
Vinicius CraveiroDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Wonduk JooDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Jennie C HolmbergDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Marta GurreaDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Yang Yang-HartwichDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Ayesha AlveroDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine; ayesha.alvero@yale.edu.
Gil MorDepartment of Obstetrics, Gynecology and Reproductive Sciences, Reproductive Immunology Unit, Yale University School of Medicine.
Yale University · USBruker (United States) · US

Funding

Apoptotic regulators in ovarian cancerR01CA118678 · NCI · YALE UNIVERSITY · PI MOR, GIL G · 2007 to 2011
$1.7M
MyD88-bearing tumors in immune-regulation and chemo-resistanceR01CA127913 · NCI · YALE UNIVERSITY · PI MOR, GIL G · 2008 to 2012
$1.7M
NCI NIH HHS R01 CA118678NCI NIH HHS R01CA118678NCI NIH HHS R01 CA127913NCI NIH HHS R01CA127913
6 · The paper itself

Abstract

Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States. Although patients initially respond to the current standard of care consisting of surgical debulking and combination chemotherapy consisting of platinum and taxane compounds, almost 90% of patients recur within a few years. In these patients the development of chemoresistant disease limits the efficacy of currently available chemotherapy agents and therefore contributes to the high mortality. To discover novel therapy options that can target recurrent disease, appropriate animal models that closely mimic the clinical profile of patients with recurrent ovarian cancer are required. The challenge in monitoring intra-peritoneal (i.p.) disease limits the use of i.p. models and thus most xenografts are established subcutaneously. We have developed a sensitive optical imaging platform that allows the detection and anatomical location of i.p. tumor mass. The platform includes the use of optical reporters that extend from the visible light range to near infrared, which in combination with 2-dimensional X-ray co-registration can provide anatomical location of molecular signals. Detection is significantly improved by the use of a rotation system that drives the animal to multiple angular positions for 360 degree imaging, allowing the identification of tumors that are not visible in single orientation. This platform provides a unique model to non-invasively monitor tumor growth and evaluate the efficacy of new therapies for the prevention or treatment of recurrent ovarian cancer.

Indexed as

Disease Models, AnimalAnimalsCarcinoma, Ovarian EpithelialFemaleHeterograftsHumansMiceMice, NudeMonitoring, PhysiologicNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialNeoplasm TransplantationOptical ImagingOvarian Neoplasms

Identifiers

PMID25407815
PMCPMC4353409
OpenAlexW1973135753

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.